IQVIA Hldgs IQV underwent analysis by 11 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 5 | 4 | 2 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 1 | 0 | 0 |
| 2M Ago | 1 | 1 | 0 | 0 | 0 |
| 3M Ago | 3 | 3 | 1 | 0 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $233.55, a high estimate of $286.00, and a low estimate of $202.00. This current average represents a 3.77% decrease from the previous average price target of $242.70.
Analyzing Analyst Ratings: A Detailed Breakdown
The standing of IQVIA Hldgs among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Jailendra Singh | Truist Securities | Raises | Buy | $286.00 | $240.00 |
| Patrick Donnelly | Citigroup | Raises | Neutral | $225.00 | $190.00 |
| Jailendra Singh | Truist Securities | Maintains | Buy | $240.00 | - |
| Anne Samuel | JP Morgan | Lowers | Overweight | $239.00 | $262.00 |
| Jailendra Singh | Truist Securities | Lowers | Buy | $240.00 | $260.00 |
| Jack Wallace | Guggenheim | Lowers | Buy | $220.00 | $253.00 |
| Tejas Savant | Morgan Stanley | Lowers | Overweight | $225.00 | $240.00 |
| Luke Sergott | Barclays | Lowers | Overweight | $215.00 | $245.00 |
| Eric Coldwell | Baird | Lowers | Neutral | $202.00 | $248.00 |
| Eric Coldwell | Baird | Raises | Outperform | $248.00 | $239.00 |
| Ann Hynes | Mizuho | Lowers | Buy | $229.00 | $250.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to IQVIA Hldgs. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of IQVIA Hldgs compared to the broader market.
- Price Targets: Gaining insights, analysts provide estimates for the future value of IQVIA Hldgs's stock. This comparison reveals trends in analysts' expectations over time.
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of IQVIA Hldgs's market position. Stay informed and make well-informed decisions with our Ratings Table.
Stay up to date on IQVIA Hldgs analyst ratings.
About IQVIA Hldgs
IQVIA is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The Research & Development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.
Financial Milestones: IQVIA Hldgs's Journey
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: IQVIA Hldgs displayed positive results in 3 months. As of 30 September, 2023, the company achieved a solid revenue growth rate of approximately 4.88%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: IQVIA Hldgs's net margin is impressive, surpassing industry averages. With a net margin of 8.11%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): IQVIA Hldgs's ROE stands out, surpassing industry averages. With an impressive ROE of 5.25%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): IQVIA Hldgs's ROA stands out, surpassing industry averages. With an impressive ROA of 1.17%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a high debt-to-equity ratio of 2.39, IQVIA Hldgs faces challenges in effectively managing its debt levels, indicating potential financial strain.
What Are Analyst Ratings?
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
